News & Publications
Press Releases
-
Improved Resection Rates in Locally Advanced Pancreatic Cancer Following Addition of Intratumoral NanoPac® to Standard of Care
November 9, 2021 by NanOlogy
-
Additional Data Presented at DDW® 2021 from a Phase 2 Clinical Trial of Intracystic NanoPac® for Mucinous Cystic Neoplasms of the Pancreas
June 9, 2021 by NanOlogy
-
NanOlogy Announces First Patient Enrollment in Lung Cancer Clinical Trial
April 26, 2021 by NanOlogy
-
NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial
March 9, 2021 by NanOlogy
NanOlogy in the News
- OncLive: LSAM-DTX Effective and Safe in NMIBC Using Direct, Multifaceted Approach
- Target Oncology: Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
- JACS: Surgery is a viable treatment for pancreatic cancer patients especially after chemotherapy
- Current Urology Reports: Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage
- Drug Development Technology: NanOlogy Starts Enrollment in NanoDoce’s Phase I/II Trial
Presentations
- ACG 2021 Presentation: Improved Resection Rates in Locally Advanced Pancreatic Cancer (LAPC) Following EUS-FNI of Large Surface Area Microparticle Paclitaxel (LSAM Pac)
- DDW 2021 Poster: Tandem EUS-Guided Fine Needle Injection of Intracystic Submicron Particle Paclitaxel (Nanopac®) as a Treatment for Branch-Duct IPMN: Safety, Pharmacokinetic, and Preliminary Efficiency
- NanOlogy General Presentation (May 2021)
- SABCS 2020 Poster: Phase 1/2 Clinical Trial of A Topical Submicron Particle Paclitaxel (SOR007) for the Treatment of Cutaneous Metastases
- ASCO 2020 Abstract: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer undergoing cytoreductive surgery
Publications
- Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 intro 4T1-Luc orthotropic implants reduces primary tumor and metastatic pulmonary lesions
- Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies
- Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery
- Investigational New Drugs: Intratumoral Submicron Particle Docetaxel Inhibits Syngeneic Renca Renal Cancer Growth & Increases CD4+, CD8+ and Treg Levels in Peripheral Blood
- Journal of Aerosol Medicine and Pulmonary Drug Delivery: Inhaled Submicron Particle Paclitaxel (NanoPac®) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer
Upcoming NanOlogy Events
Media Contacts
Opus Biotech Communications
Daniel Eramian 425-306-8716 danieleramian@comcast.net
Charles Craig 404-245-0591 charles.s.craig@gmail.com
